Therapeutic Drug Monitoring Market Size and Share Report by Product, Technology, Drug Class, End User

Description

The therapeutic drug monitoring market is estimated to generate USD 1,961.6 million in 2023, which will rise to USD 3,764.1 million, growing at a 9.8% compound annual growth rate, by 2030.

The growth of this industry is because of the rising need for genetic testing, developments in diagnostic technologies, enhancing healthcare infrastructure, and the mounting R&D expenses in healthcare.

Moreover, the industry is also boosted by the increasing product launches, the growing count of patients with chronic ailments, and the existence of helpful government regulatory guidelines and policies about the utilization of medication monitoring.

The immunoassays category, based on technology, is the largest contributor to the industry in 2023, with a 65% share, and it will remain the largest during this decade. This can be because of their high accessibility as well as rising usage in the discovery of medication analysis and development.

The equipment category, based on product, is likely to advance at a higher rate, with 10.2%, in the years to come. This can be because of the rising count of advanced equipment launches and the high R&D expenses by medical device manufacturers.

The consumables category, on the other hand, accounts for the larger therapeutic drug monitoring market share in 2023, and it will continue this trend during this decade. This can be because of the growing incidence of chronic ailments like CVDs, diabetes, and neurological disorders; along with the increasing need for precision drug dosing and tailored medication.

The commercial & private laboratories category, based on end user, is likely to propel at the fastest rate during this decade, of 10.4%. This will be because of the surging count of private laboratories around the world and the increasing need for genetic testing.

The antiepileptics category, on the basis of drug class, is leading the industry, and it will remain leading during this decade. This can be because of the increasing occurrence of epilepsy, the rising progression of anti-epileptic medications, and the surging requirement for individualized dosing.

North America is leading the industry in 2023, with a 50% share, and it will remain leading throughout this decade. This can be because of the existence of key companies, along with the government auspicious rules that permit drug monitoring mainly in primary healthcare centers and private labs.

APAC is likely to propel at the fastest rate in the years to come. This is because of the large patient populace base, increasing customer expenditure, and rising per capita income in the region.

The regional industry is also driven by the increasing economic advancement in APAC countries such as China, Japan, South Korea, and India.

With the surging need for genetic testing and enhancing healthcare infrastructure, the therapeutic drug monitoring industry will continue to progress in the coming years.

Product Code: 12735

Chapter 1. Research Scope

1.1. Research Objectives
1.2. Market Definition
1.3. Analysis Period
1.4. Market Size Breakdown by Segments
- 1.4.1. Market size breakdown, by product
- 1.4.2. Market size breakdown, by technology
- 1.4.3. Market size breakdown, by drug class
- 1.4.4. Market size breakdown, by end user
- 1.4.5. Market size breakdown, by region
1.5. Market Data Reporting Unit
- 1.5.1. Value
1.6. Key Stakeholders

Chapter 2. Research Methodology

2.1. Secondary Research
- 2.1.1. Paid
- 2.1.2. Unpaid
- 2.1.3. P&S Intelligence database
2.2. Primary Research
2.3. Market Size Estimation
2.4. Data Triangulation
2.5. Currency Conversion Rates
2.6. Assumptions for the Study
2.7. Notes and Caveats

Chapter 3. Executive Summary

Chapter 4. Market Indicators

Chapter 5. Industry Outlook

5.1. Market Dynamics
- 5.1.1. Trends
- 5.1.2. Drivers
- 5.1.3. Restraints/challenges
- 5.1.4. Impact analysis of drivers/restraints
5.2. Impact of COVID-19
5.3. Porter's Five Forces Analysis
- 5.3.1. Bargaining power of buyers
- 5.3.2. Bargaining power of suppliers
- 5.3.3. Threat of new entrants
- 5.3.4. Intensity of rivalry
- 5.3.5. Threat of substitutes

Chapter 6. Global Market

6.1. Overview
6.2. Market Revenue, by Product (2017-2030)
6.3. Market Revenue, by Technology (2017-2030)
6.4. Market Revenue, by Drug Class (2017-2030)
6.5. Market Revenue, by End User (2017-2030)
6.6. Market Revenue, by Region (2017-2030)

Chapter 7. North America Market

7.1. Overview
7.2. Market Revenue, by Product (2017-2030)
7.3. Market Revenue, by Technology (2017-2030)
7.4. Market Revenue, by Drug Class (2017-2030)
7.5. Market Revenue, by End User (2017-2030)
7.6. Market Revenue, by Country (2017-2030)

Chapter 8. Europe Market

8.1. Overview
8.2. Market Revenue, by Product (2017-2030)
8.3. Market Revenue, by Technology (2017-2030)
8.4. Market Revenue, by Drug Class (2017-2030)
8.5. Market Revenue, by End User (2017-2030)
8.6. Market Revenue, by Country (2017-2030)

Chapter 9. APAC Market

9.1. Overview
9.2. Market Revenue, by Product (2017-2030)
9.3. Market Revenue, by Technology (2017-2030)
9.4. Market Revenue, by Drug Class (2017-2030)
9.5. Market Revenue, by End User (2017-2030)
9.6. Market Revenue, by Country (2017-2030)

Chapter 10. LATAM Market

10.1. Overview
10.2. Market Revenue, by Product (2017-2030)
10.3. Market Revenue, by Technology (2017-2030)
10.4. Market Revenue, by Drug Class (2017-2030)
10.5. Market Revenue, by End User (2017-2030)
10.6. Market Revenue, by Country (2017-2030)

Chapter 11. MEA Market

11.1. Overview
11.2. Market Revenue, by Product (2017-2030)
11.3. Market Revenue, by Technology (2017-2030)
11.4. Market Revenue, by Drug Class (2017-2030)
11.5. Market Revenue, by End User (2017-2030)
11.6. Market Revenue, by Country (2017-2030)

Chapter 12. U.S. Market

12.1. Overview
12.2. Market Revenue, by Product (2017-2030)
12.3. Market Revenue, by Technology (2017-2030)
12.4. Market Revenue, by Drug Class (2017-2030)
12.5. Market Revenue, by End User (2017-2030)

Chapter 13. Canada Market

13.1. Overview
13.2. Market Revenue, by Product (2017-2030)
13.3. Market Revenue, by Technology (2017-2030)
13.4. Market Revenue, by Drug Class (2017-2030)
13.5. Market Revenue, by End User (2017-2030)

Chapter 14. Germany Market

14.1. Overview
14.2. Market Revenue, by Product (2017-2030)
14.3. Market Revenue, by Technology (2017-2030)
14.4. Market Revenue, by Drug Class (2017-2030)
14.5. Market Revenue, by End User (2017-2030)

Chapter 15. France Market

15.1. Overview
15.2. Market Revenue, by Product (2017-2030)
15.3. Market Revenue, by Technology (2017-2030)
15.4. Market Revenue, by Drug Class (2017-2030)
15.5. Market Revenue, by End User (2017-2030)

Chapter 16. U.K. Market

16.1. Overview
16.2. Market Revenue, by Product (2017-2030)
16.3. Market Revenue, by Technology (2017-2030)
16.4. Market Revenue, by Drug Class (2017-2030)
16.5. Market Revenue, by End User (2017-2030)

Chapter 17. Italy Market

17.1. Overview
17.2. Market Revenue, by Product (2017-2030)
17.3. Market Revenue, by Technology (2017-2030)
17.4. Market Revenue, by Drug Class (2017-2030)
17.5. Market Revenue, by End User (2017-2030)

Chapter 18. Spain Market

18.1. Overview
18.2. Market Revenue, by Product (2017-2030)
18.3. Market Revenue, by Technology (2017-2030)
18.4. Market Revenue, by Drug Class (2017-2030)
18.5. Market Revenue, by End User (2017-2030)

Chapter 19. Japan Market

19.1. Overview
19.2. Market Revenue, by Product (2017-2030)
19.3. Market Revenue, by Technology (2017-2030)
19.4. Market Revenue, by Drug Class (2017-2030)
19.5. Market Revenue, by End User (2017-2030)

Chapter 20. China Market

20.1. Overview
20.2. Market Revenue, by Product (2017-2030)
20.3. Market Revenue, by Technology (2017-2030)
20.4. Market Revenue, by Drug Class (2017-2030)
20.5. Market Revenue, by End User (2017-2030)

Chapter 21. India Market

21.1. Overview
21.2. Market Revenue, by Product (2017-2030)
21.3. Market Revenue, by Technology (2017-2030)
21.4. Market Revenue, by Drug Class (2017-2030)
21.5. Market Revenue, by End User (2017-2030)

Chapter 22. Australia Market

22.1. Overview
22.2. Market Revenue, by Product (2017-2030)
22.3. Market Revenue, by Technology (2017-2030)
22.4. Market Revenue, by Drug Class (2017-2030)
22.5. Market Revenue, by End User (2017-2030)

Chapter 23. South Korea Market

23.1. Overview
23.2. Market Revenue, by Product (2017-2030)
23.3. Market Revenue, by Technology (2017-2030)
23.4. Market Revenue, by Drug Class (2017-2030)
23.5. Market Revenue, by End User (2017-2030)

Chapter 24. Brazil Market

24.1. Overview
24.2. Market Revenue, by Product (2017-2030)
24.3. Market Revenue, by Technology (2017-2030)
24.4. Market Revenue, by Drug Class (2017-2030)
24.5. Market Revenue, by End User (2017-2030)

Chapter 25. Mexico Market

25.1. Overview
25.2. Market Revenue, by Product (2017-2030)
25.3. Market Revenue, by Technology (2017-2030)
25.4. Market Revenue, by Drug Class (2017-2030)
25.5. Market Revenue, by End User (2017-2030)

Chapter 26. Saudi Arabia Market

26.1. Overview
26.2. Market Revenue, by Product (2017-2030)
26.3. Market Revenue, by Technology (2017-2030)
26.4. Market Revenue, by Drug Class (2017-2030)
26.5. Market Revenue, by End User (2017-2030)

Chapter 27. South Africa Market

27.1. Overview
27.2. Market Revenue, by Product (2017-2030)
27.3. Market Revenue, by Technology (2017-2030)
27.4. Market Revenue, by Drug Class (2017-2030)
27.5. Market Revenue, by End User (2017-2030)

Chapter 28. U.A.E. Market

28.1. Overview
28.2. Market Revenue, by Product (2017-2030)
28.3. Market Revenue, by Technology (2017-2030)
28.4. Market Revenue, by Drug Class (2017-2030)
28.5. Market Revenue, by End User (2017-2030)

Chapter 29. Competitive Landscape

29.1. List of Market Players and their Offerings
29.2. Competitive Benchmarking of Key Players
29.3. Product Benchmarking of Key Players
29.4. Recent Strategic Developments

Chapter 30. Company Profiles

30.1. Abbott Laboratories
- 30.1.1. Business overview
- 30.1.2. Product and service offerings
- 30.1.3. Key financial summary
30.2. Thermo Fisher Scientific Inc.
- 30.2.1. Business overview
- 30.2.2. Product and service offerings
- 30.2.3. Key financial summary
30.3. F. Hoffmann-La Roche Ltd
- 30.3.1. Business overview
- 30.3.2. Product and service offerings
- 30.3.3. Key financial summary
30.4. Siemens Healthineers AG
- 30.4.1. Business overview
- 30.4.2. Product and service offerings
- 30.4.3. Key financial summary
30.5. BIO-RAD LABORATORIES, INC.
- 30.5.1. Business overview
- 30.5.2. Product and service offerings
- 30.5.3. Key financial summary
30.6. BIOMERIEUX S.A
- 30.6.1. Business overview
- 30.6.2. Product and service offerings
- 30.6.3. Key financial summary
30.7. EXAGEN INC.
- 30.7.1. Business overview
- 30.7.2. Product and service offerings
- 30.7.3. Key financial summary
30.8. Beckman Coulter, Inc.
- 30.8.1. Business overview
- 30.8.2. Product and service offerings
30.9. Randox Laboratories Ltd.
- 30.9.1. Business overview
- 30.9.2. Product and service offerings
30.10. SEKISUI CHEMICAL CO., LTD.
- 30.10.1. Business overview
- 30.10.2. Product and service offerings
- 30.10.3. Key financial summary
30.11. Chromsystems Instruments & Chemicals GmbH
- 30.11.1. Business overview
- 30.11.2. Product and service offerings
30.12. SJK Global, LLC.
- 30.12.1. Business overview
- 30.12.2. Product and service offerings
30.13. Alpha Laboratories Ltd.
- 30.13.1. Business overview
- 30.13.2. Product and service offerings
30.14. BUHLMANN Laboratories AG
- 30.14.1. Business overview
- 30.14.2. Product and service offerings
30.15. Modern Diagnostic & Research Centre Pvt. Ltd.
- 30.15.1. Business overview
- 30.15.2. Product and service offerings

Chapter 31. Appendix

31.1. Abbreviations
31.2. Sources and References
31.3. Related Reports

Therapeutic Drug Monitoring Market Size and Share Report by Product, Technology, Drug Class, End User - Global Industry Demand Forecast to 2030